Alpaslan Kaban
Research Subjects
Alpaslan Kaban has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Samet Topuz
Faculty of Medicine Dept. Of Obstetrics and Gynecology Division of Gynecologic Oncology Istanbul Univ Istanbul Turkey ORCID
7 shared publicationsHamdullah Sözen
Epartment of Gynecologic Oncology, İstanbul University İstanbul School of Medicine, İstanbul, Turkey
4 shared publicationsYavuz Salihoğlu
Epartment of Gynecologic Oncology, İstanbul University İstanbul School of Medicine, İstanbul, Turkey
4 shared publications- Işık Kaban
Department of Obstetrics and Gynecology, İstanbul Training and Research Hospital, İstanbul, Türkiye
3 shared publications Pınar Saip
Epartment of Gynecologic Oncology, İstanbul University İstanbul School of Medicine, İstanbul, Turkey
3 shared publications- Fatma Ferda Verit
University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul, Turkey
2 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (25) , e49188
Defining low-risk group before surgical treatment in endometrial cancer: A retrospective review
Endometrial cancer is a heterogeneous malignancy involving many criteria considered in treatment planning. This study analyzed risk factors associated with postoperative outcomes in 250 women diagnosed with endometrioid-type endometrial adenocarcinoma. The aim of this analysis was to identify the subgroup with the lowest risk of extrauterine metastasis, which could be exempted from comprehensive staging surgery. Criteria for admission to the study were endometrioid histology, grade 1 or 2 tumors, and tumor invasion of half the myometrium based on pathology reports. Extrauterine metastases, such as lymph node, fallopian tube, ovary, and omentum involvement, were evaluated. Of the 250 patients, 178 (71.2%) had grade 1 tumors and 72 (28.8%) grade 2 tumors; 152 (60.8%) had a tumor size of 3 cm or less and 98 (39.2%) had a tumor size of more than 3 cm. Eighteen patients (7.2%) had extrauterine metastases. Patients with grade 2 tumors had a higher rate of extrauterine metastases compared with those with grade 1 tumors (15.3% vs 3.9%, P = .003). Patients with tumor size >3 cm had a higher rate of extrauterine metastases compared with those with tumor size 3 cm or less (13.3% vs 3.3%, P = .006). In multivariate analysis, grade 2 (hazard ratio = 3.66, 95% confidence interval: 1.33–10.08; P = .012) and tumor size >3 cm (hazard ratio = 3.83, 95% confidence interval: 1.28–11.39; P = .016) were independent factors associated with extrauterine metastases. According to the findings of this study, among patients with endometrial cancer with <50% myometrial invasion depth, those with grade 1 tumors and tumor diameters smaller than 3 cm had the lowest rate of extrauterine metastasis. Tumor size was identified as a potential factor in determining the risk of extrauterine metastasis. These results support avoiding comprehensive staging surgery in the subgroup meeting the criteria of having a tumor smaller than 3 cm and a grade 1 endometrioid tumor.
- 19 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (25) , e49188
Open AccessDefining low-risk group before surgical treatment in endometrial cancer: A retrospective review
Endometrial cancer is a heterogeneous malignancy involving many criteria considered in treatment planning. This study analyzed risk factors associated with postoperative outcomes in 250 women diagnosed with endometrioid-type endometrial adenocarcinoma. The aim of this analysis was to identify the subgroup with the lowest risk of extrauterine metastasis, which could be exempted from comprehensive staging surgery. Criteria for admission to the study were endometrioid histology, grade 1 or 2 tumors, and tumor invasion of half the myometrium based on pathology reports. Extrauterine metastases, such as lymph node, fallopian tube, ovary, and omentum involvement, were evaluated. Of the 250 patients, 178 (71.2%) had grade 1 tumors and 72 (28.8%) grade 2 tumors; 152 (60.8%) had a tumor size of 3 cm or less and 98 (39.2%) had a tumor size of more than 3 cm. Eighteen patients (7.2%) had extrauterine metastases. Patients with grade 2 tumors had a higher rate of extrauterine metastases compared with those with grade 1 tumors (15.3% vs 3.9%, P = .003). Patients with tumor size >3 cm had a higher rate of extrauterine metastases compared with those with tumor size 3 cm or less (13.3% vs 3.3%, P = .006). In multivariate analysis, grade 2 (hazard ratio = 3.66, 95% confidence interval: 1.33–10.08; P = .012) and tumor size >3 cm (hazard ratio = 3.83, 95% confidence interval: 1.28–11.39; P = .016) were independent factors associated with extrauterine metastases. According to the findings of this study, among patients with endometrial cancer with <50% myometrial invasion depth, those with grade 1 tumors and tumor diameters smaller than 3 cm had the lowest rate of extrauterine metastasis. Tumor size was identified as a potential factor in determining the risk of extrauterine metastasis. These results support avoiding comprehensive staging surgery in the subgroup meeting the criteria of having a tumor smaller than 3 cm and a grade 1 endometrioid tumor.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 141 (4)
Short-term outcomes of COVID-19 in pregnant women unvaccinated for SARS-CoV-2 in the first, second, and third trimesters: a retrospective study
Coronavirus disease 2019 (COVID-19) may be asymptomatic or symptomatic in pregnant women. Compared to non-pregnant reproductive-aged women, symptomatic individuals appear to have a higher risk of acquiring severe illness sequelae. We assessed the clinical and laboratory characteristics and outcomes of pregnant COVID-19 patients unvaccinated for severe acute respiratory syndrome coronavirus 2 according to the trimester of pregnancy. This was a retrospective observational study conducted in a tertiary-level hospital in Turkey. This retrospective study reviewed the clinical and laboratory characteristics and outcomes of 445 pregnant COVID-19 patients hospitalized during the first, second, and third trimesters of pregnancy and 149 other pregnant women as controls in a tertiary center from April 2020 to December 2021. All participants were unvaccinated. Overall, the study groups were comparable in terms of baseline clinical pregnancy characteristics. There was no clear difference among the study participants with COVID-19 in the first, second, and third trimesters of pregnancy. However, a considerably high number of clinical and laboratory findings revealed differences that were consistent with the inflammatory nature of the disease. The study results reveal the importance of careful follow-up of hospitalized cases as a necessary step by means of regular clinical and laboratory examinations in pregnant COVID-19 patients. With further studies, after implementing vaccination programs for COVID-19 in pregnant women, these data may help determine the impact of vaccination on the outcomes of pregnant COVID-19 patients.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 141 (4)
Open AccessShort-term outcomes of COVID-19 in pregnant women unvaccinated for SARS-CoV-2 in the first, second, and third trimesters: a retrospective study
Coronavirus disease 2019 (COVID-19) may be asymptomatic or symptomatic in pregnant women. Compared to non-pregnant reproductive-aged women, symptomatic individuals appear to have a higher risk of acquiring severe illness sequelae. We assessed the clinical and laboratory characteristics and outcomes of pregnant COVID-19 patients unvaccinated for severe acute respiratory syndrome coronavirus 2 according to the trimester of pregnancy. This was a retrospective observational study conducted in a tertiary-level hospital in Turkey. This retrospective study reviewed the clinical and laboratory characteristics and outcomes of 445 pregnant COVID-19 patients hospitalized during the first, second, and third trimesters of pregnancy and 149 other pregnant women as controls in a tertiary center from April 2020 to December 2021. All participants were unvaccinated. Overall, the study groups were comparable in terms of baseline clinical pregnancy characteristics. There was no clear difference among the study participants with COVID-19 in the first, second, and third trimesters of pregnancy. However, a considerably high number of clinical and laboratory findings revealed differences that were consistent with the inflammatory nature of the disease. The study results reveal the importance of careful follow-up of hospitalized cases as a necessary step by means of regular clinical and laboratory examinations in pregnant COVID-19 patients. With further studies, after implementing vaccination programs for COVID-19 in pregnant women, these data may help determine the impact of vaccination on the outcomes of pregnant COVID-19 patients.
- 1 July 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (4) , 338-341
Comparison of Cutting Diathermy and Scalpel in Terms of Delay in Wound Healing and Scar Appearance in Skin Incision: A Prospective Observational Study
- 1 July 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (4) , 338-341
Comparison of Cutting Diathermy and Scalpel in Terms of Delay in Wound Healing and Scar Appearance in Skin Incision: A Prospective Observational Study
- 1 July 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (4) , 322-324
Negative Impact of Postoperative Early Surgical Incision Dressing: A Prospective Observational Study
- 1 July 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (4) , 322-324
Negative Impact of Postoperative Early Surgical Incision Dressing: A Prospective Observational Study
- Open Access
- 3 March 2019
- Published by Dicle Medical Journal/Dicle Tip Dergisi in Dicle Tıp Dergisi
- Vol. 46 (1) , 141-147
Survival outcomes in patients with undifferentiated endometrial carcinoma
Objective: The aim of this study was to investigate the clinicopathological features and survival of patients with undifferentiated endometrial carcinoma (UEC). Methods: Patients who were operated between 2006 and 2014 for endometrial cancer (EC) in the same center were retrospectively reviewed from the clinical archive. Data were obtained from patient files. Survival curves and rates were calculated using the Kaplan-Meier method, and differences in survival were evaluated using the Log-Rank test. Results: In this study, 774 patients with EC were screened. According to the pathology report, 14 (1.8%) had undifferentiated type histology. The mean age, parity and body mass index (BMI) of the patients were 58.6 year (range 40-73); 3.28 (range 0-6) and 32.1 kg/m2 (range 22.8-41.7), respectively. Of the patients, 64% (n=9) had deep myometrial invasion, 93% (n=13) had lymphovascular space invasion, and 57% (n=8) had cervical involvement. Tumor size was greater than 5 cm in 64% (n=9) of the patients. Thirty five percent (n=5) of the patients were stage 1A, 21% (n=3) were stage 1B, 14% (n=2) were stage 2, 14% were stage 3C, and 14% were stage 4. As adjuvant therapy, 21% (n=3) of the patients received chemotherapy only, 14% (n=2) received radiotherapy only, and 57% (n=8) received chemotherapy and radiotherapy together. The mean follow-up duration was 36 months (range 4-104). In this period, survival rates were 77% for early-stage (FIGO 1-2) and 0% for advanced-stage (FIGO 3-4). The mean survival duration was 81 months in the early stage; 6.8 months in advanced stage (Log Rank test P value= 0.001). Conclusion: According to this study, UEC is highly associated with pathological poor prognostic factors such as deep myometrial invasion, lymphovascular space invasion, cervical involvement and large tumor size. Patients with advanced stage do not have the chance to survive. Long-term survival is possible if the diagnosis and treatment of the disease is achieved while the tumor is limited to the uterus.
- 3 March 2019
- Published by Dicle Medical Journal/Dicle Tip Dergisi in Dicle Tıp Dergisi
- Vol. 46 (1) , 141-147
Open AccessSurvival outcomes in patients with undifferentiated endometrial carcinoma
Objective: The aim of this study was to investigate the clinicopathological features and survival of patients with undifferentiated endometrial carcinoma (UEC). Methods: Patients who were operated between 2006 and 2014 for endometrial cancer (EC) in the same center were retrospectively reviewed from the clinical archive. Data were obtained from patient files. Survival curves and rates were calculated using the Kaplan-Meier method, and differences in survival were evaluated using the Log-Rank test. Results: In this study, 774 patients with EC were screened. According to the pathology report, 14 (1.8%) had undifferentiated type histology. The mean age, parity and body mass index (BMI) of the patients were 58.6 year (range 40-73); 3.28 (range 0-6) and 32.1 kg/m2 (range 22.8-41.7), respectively. Of the patients, 64% (n=9) had deep myometrial invasion, 93% (n=13) had lymphovascular space invasion, and 57% (n=8) had cervical involvement. Tumor size was greater than 5 cm in 64% (n=9) of the patients. Thirty five percent (n=5) of the patients were stage 1A, 21% (n=3) were stage 1B, 14% (n=2) were stage 2, 14% were stage 3C, and 14% were stage 4. As adjuvant therapy, 21% (n=3) of the patients received chemotherapy only, 14% (n=2) received radiotherapy only, and 57% (n=8) received chemotherapy and radiotherapy together. The mean follow-up duration was 36 months (range 4-104). In this period, survival rates were 77% for early-stage (FIGO 1-2) and 0% for advanced-stage (FIGO 3-4). The mean survival duration was 81 months in the early stage; 6.8 months in advanced stage (Log Rank test P value= 0.001). Conclusion: According to this study, UEC is highly associated with pathological poor prognostic factors such as deep myometrial invasion, lymphovascular space invasion, cervical involvement and large tumor size. Patients with advanced stage do not have the chance to survive. Long-term survival is possible if the diagnosis and treatment of the disease is achieved while the tumor is limited to the uterus.
- 1 March 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (2) , 88-93
Comparison of Long-Term Survival Rates of Primary Surgery and Surgery After Neoadjuvant Chemotherapy in Ovarian Cancer
- 1 March 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (2) , 88-93
Comparison of Long-Term Survival Rates of Primary Surgery and Surgery After Neoadjuvant Chemotherapy in Ovarian Cancer
- 1 March 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (2) , 98-100
Assessment of Cervical Length by Transvaginal Ultrasound in Pregnant Women Between 24-34 Weeks
- 1 March 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (2) , 98-100
Assessment of Cervical Length by Transvaginal Ultrasound in Pregnant Women Between 24-34 Weeks
- 1 March 2019
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 20 (1) , 31-36
In patients with advanced ovarian cancer, primary suboptimal surgery has better survival outcome than interval suboptimal surgery
Objective: It is known that optimal or complete cytoreduction is the most important factor in patients with advanced ovarian cancer. The aim of this study was to examine the results of patients who did not undergo optimal cytoreduction and to examine subgroup analysis based on neoadjuvant chemotherapy (NAC). Material and Methods: Patients with advanced ovarian cancer and suboptimal surgery were retrospectively reviewed. Results: A total of 99 patients with a median age of 59.0 years (range, 22-87 years) were studied. The median follow-up time was 39 +/- 32.7 months, 81 patients (81.8%) died and 18 patients (18.2%) were alive. The five-year survival rate was 27.6%. Of the patients, 37 (37.4%) were underwent surgery after NAC, 62 (62.3%) were primary. More patients with NAC died within 3 years compared with those without NAC (83.9% vs 56.0%) (p=0.015). Patients with NAC had less tumor spread (presence of visible tumor in the upper abdomen during surgery) (29.7% vs 72.6%; p<0.001) and had less overall survival times when compared with patients who underwent primary surgery [median 22.3 +/- 1.2; 95% CI: (19.9-24.7) vs (37.5 +/- 11.2); 95% CI: (15.4-59.5) months; log rank test p=0.055]. The relationship between overall survival and factors such as age, NAC, presence of metastasis in the upper abdomen, and tumor histology (serous vs. non-serous) were analyzed using univariate cox regression analysis. Of these factors, only NAC was close to significant, but it did not reach significance (p=0.055). Conclusion: NAC reduces tumor burden before surgery in advanced ovarian cancer. The prognosis of patients who are not eligible for optimal surgery despite NAC is worse than in patients who do not receive NAC.
- 1 March 2019
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 20 (1) , 31-36
In patients with advanced ovarian cancer, primary suboptimal surgery has better survival outcome than interval suboptimal surgery
Objective: It is known that optimal or complete cytoreduction is the most important factor in patients with advanced ovarian cancer. The aim of this study was to examine the results of patients who did not undergo optimal cytoreduction and to examine subgroup analysis based on neoadjuvant chemotherapy (NAC). Material and Methods: Patients with advanced ovarian cancer and suboptimal surgery were retrospectively reviewed. Results: A total of 99 patients with a median age of 59.0 years (range, 22-87 years) were studied. The median follow-up time was 39 +/- 32.7 months, 81 patients (81.8%) died and 18 patients (18.2%) were alive. The five-year survival rate was 27.6%. Of the patients, 37 (37.4%) were underwent surgery after NAC, 62 (62.3%) were primary. More patients with NAC died within 3 years compared with those without NAC (83.9% vs 56.0%) (p=0.015). Patients with NAC had less tumor spread (presence of visible tumor in the upper abdomen during surgery) (29.7% vs 72.6%; p<0.001) and had less overall survival times when compared with patients who underwent primary surgery [median 22.3 +/- 1.2; 95% CI: (19.9-24.7) vs (37.5 +/- 11.2); 95% CI: (15.4-59.5) months; log rank test p=0.055]. The relationship between overall survival and factors such as age, NAC, presence of metastasis in the upper abdomen, and tumor histology (serous vs. non-serous) were analyzed using univariate cox regression analysis. Of these factors, only NAC was close to significant, but it did not reach significance (p=0.055). Conclusion: NAC reduces tumor burden before surgery in advanced ovarian cancer. The prognosis of patients who are not eligible for optimal surgery despite NAC is worse than in patients who do not receive NAC.
- 1 February 2019
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 41 (2) , 160-165
Does the Increased Rate of Serous Component (≤25% vs. >25%) Increase Recurrence in Endometrial Cancer With Serous Plus Endometrioid Histology?
- 1 February 2019
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 41 (2) , 160-165
Does the Increased Rate of Serous Component (≤25% vs. >25%) Increase Recurrence in Endometrial Cancer With Serous Plus Endometrioid Histology?
- Open Access
- 1 January 2019
- Published by Kare Publishing in SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital
- Vol. 53 (3) , 252-255
Investigation of extra-uterine tumor dissemination of endometrial cancers with myometrial invasion less than 50% according to hystologic subtypes
The Medical Bulletin of Sisli Etfal Hospital
- 1 January 2019
- Published by Kare Publishing in SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital
- Vol. 53 (3) , 252-255
Open AccessInvestigation of extra-uterine tumor dissemination of endometrial cancers with myometrial invasion less than 50% according to hystologic subtypes
The Medical Bulletin of Sisli Etfal Hospital